HeartBeam Inc. (NASDAQ: BEAT) announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss its first-quarter financial results for the period ended March 31, 2026, and provide updates on key growth initiatives. The call will cover the company's limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and artificial intelligence programs, according to a press release.
The announcement comes as HeartBeam advances its 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. The company's platform is designed to enable cable-free, portable devices that collect ECG signals from three non-coplanar directions and synthesize them into a 12-lead ECG, allowing physicians to monitor cardiac health trends and acute conditions outside of medical facilities.
HeartBeam's limited commercial launch for arrhythmia assessment represents a critical step toward bringing its technology to market. The company is also developing an extended-wear patch for continuous monitoring and working on heart attack detection capabilities. Its AI programs aim to enhance diagnostic accuracy and clinical decision-making.
The company holds over 20 issued patents related to its technology enablement. Investors and analysts will be watching for updates on commercialization progress, regulatory milestones, and financial performance during the call.
For more details on the company's technology and cleared indications for use, visit the HeartBeam website at https://www.heartbeam.com/indications. The latest news and updates on BEAT are available in the company's newsroom at https://nnw.fm/BEAT.
The conference call will be accessible via a live webcast on the company's investor relations page. A replay will be available after the call.
